$124.25
0[0.00%]
Last update: 4:05PM Get Real Time Here
Sarepta Therapeutics
(NASDAQ:SRPT)Sarepta Therapeutics Stock (NASDAQ:SRPT), Analyst Ratings, Price Targets, Predictions
Sarepta Therapeutics Inc has a consensus price target of $164.22, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from UBS, Cantor Fitzgerald, and RBC Capital on March 1, 2024, February 29, 2024, and February 29, 2024. With an average price target of $150.67 between UBS, Cantor Fitzgerald, and RBC Capital, there's an implied 17.25% upside for Sarepta Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
UBS
Cantor Fitzgerald
RBC Capital
Citigroup
Barclays
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Sarepta Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/01/2024 | SRPT | Buy Now | Sarepta Therapeutics | $128.50 | 29.96% | UBS | Colin Bristow | $164 → $167 | Maintains | Buy | Get Alert |
| 02/29/2024 | SRPT | Buy Now | Sarepta Therapeutics | $128.50 | -0.39% | Cantor Fitzgerald | Kristen Kluska | → $128 | Reiterates | Neutral → Neutral | Get Alert |
| 02/29/2024 | SRPT | Buy Now | Sarepta Therapeutics | $128.50 | 22.18% | RBC Capital | Brian Abrahams | $151 → $157 | Maintains | Outperform | Get Alert |
| 02/29/2024 | SRPT | Buy Now | Sarepta Therapeutics | $128.50 | 33.85% | Citigroup | David Hoang | $160 → $172 | Maintains | Buy | Get Alert |
| 02/29/2024 | SRPT | Buy Now | Sarepta Therapeutics | $128.50 | 43.97% | Barclays | Gena Wang | $141 → $185 | Maintains | Overweight | Get Alert |
| 02/29/2024 | SRPT | Buy Now | Sarepta Therapeutics | $128.50 | 29.18% | Needham | Gil Blum | $169 → $166 | Maintains | Buy | Get Alert |
| 02/20/2024 | SRPT | Buy Now | Sarepta Therapeutics | $128.50 | 7.39% | Evercore ISI Group | Gavin Clark-Gartner | $108 → $138 | Maintains | In-Line | Get Alert |
| 02/20/2024 | SRPT | Buy Now | Sarepta Therapeutics | $128.50 | 74.32% | Wedbush | Andreas Argyrides | → $224 | Reiterates | Outperform → Outperform | Get Alert |
| 02/16/2024 | SRPT | Buy Now | Sarepta Therapeutics | $128.50 | 31.52% | Needham | Gil Blum | $140 → $169 | Maintains | Buy | Get Alert |
| 02/15/2024 | SRPT | Buy Now | Sarepta Therapeutics | $128.50 | -0.39% | Cantor Fitzgerald | Kristen Kluska | → $128 | Reiterates | Neutral → Neutral | Get Alert |
| 02/14/2024 | SRPT | Buy Now | Sarepta Therapeutics | $128.50 | 12.84% | Mizuho | Uy Ear | $130 → $145 | Maintains | Buy | Get Alert |
| 02/14/2024 | SRPT | Buy Now | Sarepta Therapeutics | $128.50 | -0.39% | Cantor Fitzgerald | Kristen Kluska | → $128 | Reiterates | Neutral → Neutral | Get Alert |
| 01/31/2024 | SRPT | Buy Now | Sarepta Therapeutics | $128.50 | 32.3% | BMO Capital | Kostas Biliouris | → $170 | Initiates | → Outperform | Get Alert |
| 01/30/2024 | SRPT | Buy Now | Sarepta Therapeutics | $128.50 | 74.32% | Wedbush | Andreas Argyrides | → $224 | Reiterates | Outperform → Outperform | Get Alert |
| 01/29/2024 | SRPT | Buy Now | Sarepta Therapeutics | $128.50 | 8.95% | Needham | Gil Blum | → $140 | Reiterates | Buy → Buy | Get Alert |
| 01/25/2024 | SRPT | Buy Now | Sarepta Therapeutics | $128.50 | 17.51% | RBC Capital | Brian Abrahams | $155 → $151 | Maintains | Outperform | Get Alert |
| 01/10/2024 | SRPT | Buy Now | Sarepta Therapeutics | $128.50 | 8.95% | Needham | Gil Blum | $93 → $140 | Maintains | Buy | Get Alert |
| 01/09/2024 | SRPT | Buy Now | Sarepta Therapeutics | $128.50 | 74.32% | Wedbush | Andreas Argyrides | → $224 | Reiterates | Outperform → Outperform | Get Alert |
| 12/13/2023 | SRPT | Buy Now | Sarepta Therapeutics | $128.50 | -12.06% | Citigroup | David Hoang | → $113 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Sarepta Therapeutics (SRPT)?
The latest price target for Sarepta Therapeutics (NASDAQ: SRPT) was reported by UBS on March 1, 2024. The analyst firm set a price target for $167.00 expecting SRPT to rise to within 12 months (a possible 34.41% upside). 61 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sarepta Therapeutics (SRPT)?
The latest analyst rating for Sarepta Therapeutics (NASDAQ: SRPT) was provided by UBS, and Sarepta Therapeutics maintained their buy rating.
When was the last upgrade for Sarepta Therapeutics (SRPT)?
The last upgrade for Sarepta Therapeutics Inc happened on March 1, 2023 when Morgan Stanley raised their price target to $187. Morgan Stanley previously had an equal-weight for Sarepta Therapeutics Inc.
When was the last downgrade for Sarepta Therapeutics (SRPT)?
The last downgrade for Sarepta Therapeutics Inc happened on October 31, 2023 when Cantor Fitzgerald changed their price target from $166 to $40 for Sarepta Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Sarepta Therapeutics (SRPT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sarepta Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sarepta Therapeutics was filed on March 1, 2024 so you should expect the next rating to be made available sometime around March 1, 2025.
Is the Analyst Rating Sarepta Therapeutics (SRPT) correct?
While ratings are subjective and will change, the latest Sarepta Therapeutics (SRPT) rating was a maintained with a price target of $164.00 to $167.00. The current price Sarepta Therapeutics (SRPT) is trading at is $124.25, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.